SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY's trend is currently dominated by intense global energy market turmoil fueled by the escalating Iran war, which has sent oil prices soaring and ignited community concerns over inflation and a potential market correction.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending due to escalating Middle East conflict, causing oil production cuts and uncertainty around the Strait of Hormuz, while the G7 considers a coordinated strategic reserve release. The community is sharply divided, with some anticipating further price surges from supply shocks and others expecting a swift reversal as interventions loom.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending as escalating Middle East tensions, with reports of oil infrastructure strikes and disrupted shipping in the Strait of Hormuz, are fueling a rapid surge in crude prices. The community is actively discussing a potential massive short squeeze and significant rally for this low-float oil play, drawing parallels to its past performance during similar geopolitical spikes.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is trending as escalating geopolitical tensions in the Middle East drive a significant surge in crude oil prices, fueling broad market uncertainty and concerns over inflation. The community is sharply divided between those anticipating a deep market correction or "Black Monday" and those expecting a "buy the dip" opportunity and a rapid V-shaped recovery for tech and growth names.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is buzzing after a cryptic tweet from 'Roaring Kitty' reignited fervent community speculation about an impending short squeeze and the company's business transformation under Ryan Cohen, further fueled by high short interest and bullish technical indicators.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending as reports circulate about an imminent partnership with Novo Nordisk to distribute GLP-1 obesity drugs, sparking massive bullish sentiment and calls for a significant short squeeze among the community, which had seen the stock pressured by previous legal disputes and high short interest.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as investors anticipate its upcoming earnings report, with community sentiment sharply divided between those highlighting its deeply oversold status, strong AI advancements, and a recent Goldman Sachs 'Conviction Buy' upgrade. Conversely, significant geopolitical and regulatory concerns continue to weigh on the broader Chinese tech sector, driving heated discussions.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil ($SCO) is trending amidst surging crude oil prices driven by escalating Middle East tensions and concerns over the Strait of Hormuz. The community is actively positioning in this inverse ETF, anticipating an eventual significant pullback in oil, even as some question SCO's 2x tracking accuracy and discuss trading halts.

ProShares Trust - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Escalating geopolitical tensions in the Middle East, driven by reports of critical oil infrastructure attacks and potential disruptions in the Strait of Hormuz, are causing UCO to surge as traders brace for significant supply shortages. The community is actively debating whether this rally will drive oil to new highs or if persistent oversupply concerns and diplomatic progress will eventually trigger a reversal.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares (SOXL) is experiencing significant volatility amid fluctuating oil prices driven by geopolitical tensions and reports of potential oil reserve releases. The community is sharply divided between 'buy the dip' and calls for a deeper correction, with traders actively discussing the impact of these macro events on chip demand and anticipating upcoming earnings from major semiconductor companies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Value Stocks to Buy for May 28th

New Strong Buy Stocks for May 28th

Shares of Phio Pharmaceuticals Corp. (PHIO) traded 63% higher on Wednesday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://phiopharma.com/phio-pharmaceuticals-announces-positive-safety-monitoring-committee-recommendation-to-advance-intasyl-ph-762-skin-cancer-study-to-fourth-dose-escalation-cohort/">announced</a> that a Safety Monitoring Committee (SMC) recommended escalating the dose in the clinical trial for its lead product candidate, PH-762.The dose-escalating clinical trial aims to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in certain skin cancers. The trial assesses tumor response and determines the recommended dose for further study of the product candidate.PH-762 is an Intasyl compound that silences the PD-1 gene implicated in various forms of skin cancer.CEO Robert Bitterman said the company is optimistic the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer.The company said that two of four patients diagnosed with cutaneous squamous cell carcinoma and enrolled in the second cohort of the trial had 100% tumor clearance upon excision.While one had a 90% tumor clearance, the fourth patient maintained stable disease, the company said.Three patients were enrolled in the third cohort of the trials. The injections were well tolerated with no serious adverse events, the company said.On Stocktwits, retail sentiment around Phio Pharmaceuticals rose from ‘bearish’ to ‘extremely bullish’ while message volume jumped from ‘high’ to ‘extremely high’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:1298/298;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_09_at_1_47_54_PM_png_f2666fba4f.webp" alt="PHIO's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 9, 2025 | Source: Stocktwits" width="1298" height="298"><figcaption>PHIO's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/PHIO">PHIO shares</a> rose as high as $2.73 on Wednesday before paring gains to around $1.50.The stock fell by over 13% this year and by over 73% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pacbio-plans-to-reduce-spending-over-nih-funding-uncertainty-tariffs/chfnXrfRbBd">PacBio Stock Soars On Plans To Reduce Spending Over NIH Funding Uncertainty, Tariffs: Retail Is Overjoyed</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Phio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s Thrilled

CEO Robert Bitterman said the company is optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer. 

Equity

CEO Robert Bitterman said the company is optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer.

Shares of Phio Pharmaceuticals Corp. (PHIO) nearly&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/phio-stock-rockets-on-cancer-trial-data/chGNgCORNj">quadrupled</a> on Monday after the biotech firm announced promising results from its Phase 1b trial for the cancer immunotherapy PH-762, designed to enhance the immune system's ability to target tumors.However, the nanocap stock reversed course on Tuesday, plunging over 50% following news of a registered direct offering.Phio revealed agreements to sell 1.1 million common shares at $3 each, with a concurrent private placement issuing short-term warrants to purchase 2.1 million shares at the same price.&nbsp;The combined transactions are expected to generate approximately $3.2 million in gross proceeds, earmarked for working capital and other corporate purposes.Despite the sharp decline, retail investors remain optimistic, as evidenced by a Stocktwits poll where nearly 50% of over 900 participants believe the stock has "more room to run."&nbsp;Around 34% foresee a pullback, while 13% are uncertain due to the stock's volatility.Retail sentiment on Stocktwits turned 'extremely bullish' on Tuesday, with many users predicting a post-offering rally fueled by Phio's low float and the potential of its drug pipeline.&nbsp;Some highlighted the company's ongoing trial progress, while others saw the price drop as a buying opportunity.<stembedurl>https://stocktwits.com/pragash2094/message/599992949</stembedurl><stembedurl>https://stocktwits.com/HUBC1/message/599986181</stembedurl><stembedurl>https://stocktwits.com/TrendIsMyFriend/message/599998502</stembedurl>Like many early-stage biotech firms, Phio has yet to generate revenue. However, its latest financial report showed narrowed losses of $1.5 million for the quarter ended Sept. 30, compared to $2.8 million a year earlier.&nbsp;The company reported $5.4 million in cash, down from $8.4 million a year earlier but more than $4.7 million at the end of the previous quarter.The stock has lost nearly 50% of its value over the past year but has seen retail interest soar. The number of new followers on Stocktwits jumped by over 9%, while message volume increased more than 1,600-fold.With a short interest of 3.8% and ongoing developments in its PH-762 trial, retail investors remain laser-focused on updates about higher-dose concentrations and further enrollment milestones.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Phio’s stock has lost nearly 50% of its value over the past year but has seen retail interest soar. | Image source: Maria Korneeva on Getty Images

We Asked Retail What's Next For Phio Pharma After Monday's Blistering Rally: Most See More Room To Run

Around 34% foresee a pullback, while 13% are uncertain due to the stock's volatility.

Shares of Phio Pharmaceuticals Corp. surged 330% Monday afternoon, reaching their highest levels in nearly eight months, to become the top gainer across U.S. bourses.&nbsp;This explosive move followed the announcement of positive results from a Phase 1b trial of its cancer treatment, PH-762, which is designed to enhance the immune system’s ability to target tumors.&nbsp;Trading volume soared to over 220 times the daily average, drawing significant attention from retail investors.Phio revealed that patients in the second cohort of its ongoing trial exhibited these pathologic responses: Two patients with cutaneous squamous cell carcinoma experienced a complete response (100% tumor clearance); one patient had a partial response (90% tumor clearance); one patient maintained stable disease, with no progression.The trial focuses on evaluating PH-762 for neoadjuvant use in Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma.&nbsp;Importantly, no dose-limiting toxicities or clinically relevant adverse events have been reported, and the intratumoral injections have been well tolerated, the company said.Mary Spellman, Acting chief medical officer of Phio, expressed optimism about the tumor responses, saying, “We look forward to continued enrollment which will permit assessment of higher dose concentrations of PH-762.”&nbsp;"These positive results in the early stages of dose escalation offer promise for our vision, 'striving for a cancer free future' using INTASYL technology" said CEO Robert Bitterman.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/PHIO_sentiment_meter_and_message_volume_Jan_13_38cb5ff222.png" alt="PHIO sentiment meter and message volume Jan 13.png" width="1318" height="324"><figcaption>PHIO sentiment meter and message volume Jan 13 as of 12:15 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for Phio spiked to 'extremely bullish' levels, with users sharing optimistic price targets and success stories.<stembedurl>https://stocktwits.com/M105/message/599814732</stembedurl><stembedurl>https://stocktwits.com/Ian980/message/599806765</stembedurl><a href="https://stocktwits.com/symbol/PHIO">Phio’s stock</a> has gained nearly 15% over the past 12 months, with Monday’s rally marking a sharp shift in momentum.&nbsp;Investors are closely watching for further enrollment updates and results from higher dose concentrations in the ongoing trial.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The trial focuses on evaluating PH-762 for neoadjuvant use in Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma. | Image source: Getty Images

Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated

CEO Robert Bitterman highlighted the potential of Phio’s proprietary INTASYL RNAi technology, which targets proteins that hinder the body’s immune response to cancer.

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Current Price	$1.16
Prev Close	$1.17
Open	$1.17
Dividend Yield	0.00%
50-Day Moving Average	$1.10
Beta	1.12
Avg. Volume	11.48M
PE Ratio	-0.77

52-Week High	$4.19
52-Week Low	$0.8127
Market Capitalization	$13.48M
EPS (Annual)	-$1.45
Price to Book	0.67
Revenue Per Employee	$0.00

PHIO
Phio Pharmaceuticals Corp

Feed

News

Sentiment

Fundamentals

Info

Latest PHIO News

PHIOPhio Pharmaceuticals Corp